GlassScriptPhysician profile
Lynn Wheeler
NPI 1295039873
$8,206.09
in general payments reported to CMS, 2019-2025
24 companies · $2,645 in 2025
The $2,645 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,063 · 2023: $2,109 · 2024: $2,389 · 2025: $2,645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,138 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,137.73 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $857.95 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $796.93 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $759.11 | 2022-2025 | Ingrezza |
| Abbvie INC. | $696.46 | 2023-2025 | |
| Axsome Therapeutics, INC. | $666.91 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $597.49 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $576.11 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $532.94 | 2022-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $518.07 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Ironshore Pharmaceuticals INC. | $502.21 | 2022-2024 | Jornay Pm |
| Corium, LLC | $421.26 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $329.71 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $187.31 | 2022-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $150.22 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $143.86 | 2025 | Jornay Pm |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $116.46 | 2023-2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $97.74 | 2024-2025 | Hetlioz, Fanapt |
| Indivior INC. | $83.68 | 2022 | |
| Livanova USA, INC. | $46.38 | 2024-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Brainsway USA INC | $41.86 | 2023 | |
| Almatica Pharma LLC | $32.58 | 2022-2023 | Sertraline Hcl, Loreev Xr |
| Bausch Health US, LLC | $21.32 | 2023 | Aplenzin |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.47 | 2024 | Rejoyn |
| Eisai INC. | $13.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.